Status:
COMPLETED
A Study to Gather Information About User Satisfaction in Women in Russia Who Take Estradiol Valerate/Dienogest
Lead Sponsor:
Bayer
Conditions:
Oral Contraception
Eligibility:
FEMALE
18-35 years
Brief Summary
Researchers want to learn more about user satisfaction in women in Russia who take estradiol valerate/ dienogest as a contraceptive in real conditions. Estradiol valerate/ dienogest is a form of birt...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Age from 18 to 35 y.o.
- Indications for administration of estradiol valerate/ dienogest for the purpose of oral contraception.
- Patients who did not take estradiol valerate/ dienogest for at least one month before enrollment into the study.
- Signed informed consent to participate in the study
- Exclusion criteria
- Participation in an investigational program with interventions outside of routine clinical practice.
- Contraindications to estradiol valerate/ dienogest according to the local market authorization.
- Any medical and non-medical reasons that according to the physician's judgment may prevent patient's participation in the non-interventional study.
Exclusion
Key Trial Info
Start Date :
June 24 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 20 2023
Estimated Enrollment :
255 Patients enrolled
Trial Details
Trial ID
NCT04901377
Start Date
June 24 2021
End Date
April 20 2023
Last Update
September 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many locations
Multiple Locations, Russia